Clinical Trial Update: Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating isavuconazole to prevent COVID-19-associated pulmonary aspergillosis; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis Invasive
• Respiratory Syndrome Coronavirus 2

Drugs mentioned

• Isavuconazole (Isavuconazole)

Snippet

Sponsor: Jeffrey Jenks, MD, MPH | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive | Phase 3 | Status: TERMINATED